Xigduo™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes

AstraZeneca and Bristol-Myers Squibb today announced that Xigduo™ (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (AstraZeneca)